The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Hyperprolactinemia and Prolactinomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ezzat, S., Zheng, L., Zhu, X.-F., Wu, G. E., & Asa, S. L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14036 · Cited by 179
RetractedProlactin: structure, function, and regulation of secretion
Freeman, M. E., Kanyicska, B., Lerant, A., & Nagy, G. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1523 · Cited by 2,457
Bole-Feysot, C., Goffin, V., Edery, M., Binart, N., & Kelly, P. A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0334 · Cited by 1,938
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Criteria for Cure of Acromegaly: A Consensus Statement
Giustina, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.526 · Cited by 987
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationStratakis, C. A., Kirschner, L. S., & Carney, J. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4041 · Cited by 826
Advances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Hall, W. A., Luciano, M. G., Doppman, J. L., Patronas, N. J., & Oldfield, E. H. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-10-199405150-00001 · Cited by 627
PENICILUNASE-PRODUCING NEISSERIA GONORRH$OElig;q
ASHFORD, W. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92467-3 · Cited by 557
Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study
Vergès, B., Boureille, F., Goudet, P., Murat, A., Beckers, A., Sassolas, G., Cougard, P., Chambe, B., Montvernay, C., & Calender, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8145 · Cited by 483
Bôle‐Feysot, C. (1998) · Endocrine Reviews · doi:10.1210/er.19.3.225 · Cited by 477
Human Prolactin: 24-Hour Pattern with Increased Release during Sleep
Sassin, J. F., Frantz, A. G., Weitzman, E. D., & Kapen, S. (1972) · Science · doi:10.1126/science.177.4055.1205 · Cited by 460
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5810 · Cited by 449
MOLITCH, M. E., ELTON, R. L., BLACKWELL, R. E., CALDWELL, B., CHANG, R. J., JAFFE, R., JOPLIN, G., ROBBINS, R. J., TYSON, J., & THORNER, M. O. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-4-698 · Cited by 435
Structural Variants of Prolactin: Occurrence and Physiological Significance
SINHA, Y. N. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-354 · Cited by 433
Decreased Bone Density in Hyperprolactinemic Women
Klibanski, A., Neer, R. M., Beitins, I. Z., Ridgway, E. C., Zervas, N. T., & McArthur, J. W. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032605 · Cited by 360
de Burbure, C., Buchet, J.-P., Leroyer, A., Nisse, C., Haguenoer, J.-M., Mutti, A., Smerhovský, Z., Cikrt, M., Trzcinka-Ochocka, M., Razniewska, G., et al. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.8202 · Cited by 345
Frontiers in neuroendocrinology
Fink, G. (1979) · Neuroscience · doi:10.1016/0306-4522(79)90148-9 · Cited by 343
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R., & Lombardi, G. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022657 · Cited by 336
Daly, A. F., Vanbellinghen, J.-F., Khoo, S. K., Jaffrain-Rea, M.-L., Naves, L. A., Guitelman, M. A., Murat, A., Emy, P., Gimenez-Roqueplo, A.-P., Tamburrano, G., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2513 · Cited by 326
Diagnosis and Management of Pituitary Carcinomas
Kaltsas, G. A., Nomikos, P., Kontogeorgos, G., Buchfelder, M., & Grossman, A. B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2231 · Cited by 325
Age‐related and gender‐related occurrence of pituitary adenomas
Mindermann, T., & Wilson, C. B. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02557.x · Cited by 304
The Epidemiology of Prolactinomas
Ciccarelli, A., Daly, A. F., & Beckers, A. (2005) · Pituitary · doi:10.1007/s11102-005-5079-0 · Cited by 286
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
The Natural History of Untreated Hyperprolactinemia: A Prospective Analysis*
SCHLECHTE, J., DOLAN, K., SHERMAN, B., CHAPLER, F., & LUCIANO, A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-412 · Cited by 271
Resistance to Bromocriptine in Prolactinomas
PELLEGRINI, I., RASOLONJANAHARY, R., GUNZ, G., BERTRAND, P., DELIVET, S., JEDYNAK, C. P., KORDON, C., PEILLON, F., JAQUET, P., & ENJALBERT, A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-500 · Cited by 267
Colao, A., Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R., Somma, C., Faggiano, A., Biondi, B., & Lombardi, G. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480325 · Cited by 267
Shimon, I., Yan, X., Taylor, J. E., Weiss, M. H., Culler, M. D., & Melmed, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119779 · Cited by 260
Schlechte, J. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp025334 · Cited by 258
Pregnancy and the Hyperprolactinemic Woman
Molitch, M. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505233122106 · Cited by 254
Medication-Induced Hyperprolactinemia
Molitch, M. E. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1050 · Cited by 250
De Marinis, L., Bonadonna, S., Bianchi, A., Maira, G., & Giustina, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0288 · Cited by 250
Self-citationSevere multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
Horvath, J., Fross, R. D., Kleiner‐Fisman, G., Lerch, R., Stalder, H., Liaudat, S., Raskoff, W. J., Flachsbart, K. D., Rakowski, H., Pache, J., et al. (2004) · Movement Disorders · doi:10.1002/mds.20201 · Cited by 243
Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging.
Elster, A. D., Sanders, T. G., Vines, F. S., & Chen, M. Y. (1991) · Radiology · doi:10.1148/radiology.181.2.1924800 · Cited by 230
Colao, A., Di Sarno, A., Landi, M. L., Scavuzzo, F., Cappabianca, P., Pivonello, R., Volpe, R., Di Salle, F., Cirillo, S., Annunziato, L., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6657 · Cited by 227
HORSEMAN, N. D., & YU-LEE, L.-Y. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-5-627 · Cited by 224
Reproductive role of prolactin
Bachelot, A., & Binart, N. (2007) · Reproduction · doi:10.1530/rep-06-0299 · Cited by 224
Outcome of Pregnancy in Women with Pituitary Adenoma
Wallach, E., Gemzell, C., & Wang, C. F. (1979) · Fertility and Sterility · doi:10.1016/s0015-0282(16)43929-4 · Cited by 206
Increase in Bone Mass after Treatment of Hyperprolactinemic Amenorrhea
Klibanski, A., & Greenspan, S. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608283150903 · Cited by 205
Bakowska, J. C., & Morrell, J. I. (1997) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19970922)386:2<161::aid-cne1>3.0.co;2-# · Cited by 199
Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists
Goffin, V., Bernichtein, S., Touraine, P., & Kelly, P. A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0016 · Cited by 199
Pituitary Tumor Registry: A Novel Clinical Resource
Drange, M. R., Fram, N. R., Herman-Bonert, V. S., & Melmed, S. K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6309 · Cited by 199
Pharmacologic Resistance in Prolactinoma Patients
Molitch, M. E. (2005) · Pituitary · doi:10.1007/s11102-005-5085-2 · Cited by 194
Webster, J. (1996) · Drug Safety · doi:10.2165/00002018-199614040-00003 · Cited by 186
Hofland, L. J., van der Hoek, J., van Koetsveld, P. M., de Herder, W. W., Waaijers, M., Sprij-Mooij, D., Bruns, C., Weckbecker, G., Feelders, R., van der Lely, A.-J., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031344 · Cited by 185
DISORDERS OF PROLACTIN SECRETION
Molitch, M. E. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70203-6 · Cited by 182
Surgical Treatment of Prolactin-Secreting Pituitary Adenomas: Early Results and Long-Term Outcome
Losa, M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3180 · Cited by 181
Pregnancy outcome after treatment with the ergot derivative, cabergoline
Robert, E., Musatti, L., Piscitelli, G., & Ferrari, C. I. (1996) · Reproductive Toxicology · doi:10.1016/0890-6238(96)00063-9 · Cited by 178
Oxford Handbook of Endocrinology and Diabetes
(2014) · doi:10.1093/med/9780199644438.001.0001 · Cited by 177
Caccavelli, L., Feron, F., Morange, I., Rouer, E., Benarous, R., Dewailly, D., Jaquet, P., Kordon, C., & Enjalbert, A. (1994) · Neuroendocrinology · doi:10.1159/000126764 · Cited by 173
MEDICAL TREATMENT OF PROLACTINOMAS
Molitch, M. E. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70061-x · Cited by 171
Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage
Colao, A., Di Sarno, A., Landi, M. L., Cirillo, S., Sarnacchiaro, F., Facciolli, G., Pivonello, R., Cataldi, M., Merola, B., Annunziato, L., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.11.4368 · Cited by 163
The Impact on Clinical Practice of Routine Screening for Macroprolactin
Gibney, J., Smith, T. P., & McKenna, T. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2234 · Cited by 159
Pregnancy outcome after cabergoline treatment in early weeks of gestation
Ricci, E. D., Parazzini, F., Motta, T., Ferrari, C. I., Colao, A., Clavenna, A., Rocchi, F., Gangi, E., Paracchi, S., Gasperi, M., et al. (2002) · Reproductive Toxicology · doi:10.1016/s0890-6238(02)00055-2 · Cited by 157
Treatment of macroprolactinoma with cabergoline: a study of 85 patients
Ferrari, C. I., Abs, R., Bevan, J. S., Brabant, G. E., CICCARELLI, E., Motta, T., Mucci, M., Muratori, M., Musatti, L., Verbessem, G., et al. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1300952.x · Cited by 154
Thyroid Hormone Inhibition of the Prolactin Response to Thyrotropin-Releasing Hormone
Snyder, P. J., JACOBS, L. S., Utiger, R. D., & Daughaday, W. H. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107421 · Cited by 153
Bromocriptine in pregnancy: Safety aspects
Krupp, P., & Monka, C. (1987) · Journal of Molecular Medicine · doi:10.1007/bf01727477 · Cited by 150
Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas
March, C. M., Kletzky, O. A., Davajan, V., Teal, J. S., Weiss, M., Apuzzo, M. L. J., Marrs, R. P., & Mishell, D. R. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90553-6 · Cited by 149
Cabergoline in the long-term therapy of hyperprolactinemic disorders
Ferrari, C., PARACCHI, A., MATTEI, A. M., de Vincentiis, S., D'Alberton, A., & Crosignani, P. (1992) · European Journal of Endocrinology · doi:10.1530/acta.0.1260489 · Cited by 146
Rains, C. P., Bryson, H. M., & Fitton, A. (1995) · Drugs · doi:10.2165/00003495-199549020-00009 · Cited by 142
Visual Loss in Pregnant Women with Pituitary Adenomas
Kupersmith, M. J., Rosenberg, C., & Kleinberg, D. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-7-199410010-00001 · Cited by 142
Giustina, A., & Wehrenberg, W. (1992) · Trends in endocrinology and metabolism · doi:10.1016/1043-2760(92)90142-n · Cited by 130
Self-citationEffectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men
Shimon, I., Benbassat, C. A., & Hadani, M. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0646 · Cited by 130
Long‐term follow‐up of patients with hyperprolactinaemia
Jeffcoate, W. J., Pound, N., Sturrock, N. D. C., & Lambourne, J. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00824.x · Cited by 129
Ferrari, C. I., BARBIERI, C., CALDARA, R., MUCCI, M., CODECASA, F., PARACCHI, A., Romano, C., Boghen, M. F., & Dubini, A. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-4-941 · Cited by 127
Rosa, M. D., Colao, A. A. L., Sarno, A. D., Ferone, D., Landi, M. L., Zarrilli, S., Paesano, L., Merola, B., & Lombardi, G. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380286 · Cited by 127
Marchant, J. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90103-8 · Cited by 127
Kovács, K., Ştefăneanu, L., Ezzat, S., & Smyth, H. S. (1994) · PubMed · Cited by 125
Oxford Textbook of Endocrinology and Diabetes
Jessop, D. (2002) · Oxford University Press eBooks · Cited by 123
Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
Álvarez-Nemegyei, J., Cobarrubias-Cobos, A., Escalante-Triay, F., Sosa-Muüoz, J., Miranda, J. M., & Jara, L. J. (1998) · Lupus · doi:10.1191/096120398678920334 · Cited by 123
Bronstein, M. D. (2005) · Pituitary · doi:10.1007/s11102-005-5083-4 · Cited by 123
Psychotic reactions during treatment of pituitary tumours with dopamine agonists.
Turner, T. H., Cookson, J., Wass, J. A. H., Drury, P. L., Price, P. A., & Besser, G. M. (1984) · BMJ · doi:10.1136/bmj.289.6452.1101 · Cited by 122
Biswas, M., Smith, J., Jadon, D. R., McEwan, P. C., Rees, A., Evans, M., Scanlon, M. F., & Davies, J. S. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02293.x · Cited by 122
Follow-Up of Children Born of Bromocriptine-Treated Mothers
Raymond, J. P., Goldstein, E., Konopka, P., Leleu, M. F., Merceron, R. E., & Loria, Y. (2008) · Hormone Research · doi:10.1159/000180100 · Cited by 120
CURRENT APPROACHES TO IMAGING OF THE SELLAR REGION AND PITUITARY
Naidich, M. J., & Russell, E. J. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70057-8 · Cited by 119
Complications after trans-sphenoidal surgery: our experience and a review of the literature
Sudhakar, N., Ray, A. K., & Vafidis, J. A. (2004) · British Journal of Neurosurgery · doi:10.1080/02688690400012459a · Cited by 117
Bevan, J. S., ADAMS, C. B. T., Burke, C. W., MORTON, K. E., Molyneux, A., Moore, A., & Esiri, M. M. (1987) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1987.tb00809.x · Cited by 117
Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males
Di Somma, C. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.3.807 · Cited by 117
Carta, P., Flore, C., Alinovi, R., Ibba, A., Tocco, M. G., Aru, G., Carta, R., Girei, E., Mutti, A., Lucchini, R. G., et al. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00080-9 · Cited by 114
Gürlek, A., Karavitaki, N., Ansorge, O., & Wass, J. A. H. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02339 · Cited by 113
Kok, P., Roelfsema, F., Frölich, M., PELT, J. V., Stokkel, M. P. M., Meinders, A. E., & Pijl, H. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00567.2005 · Cited by 111
Natural History of Microprolactinomas: Six-Year Follow-up
Weiss, M. H., Teal, J. S., Gott, P. S., Wycoff, R., Yadley, R. A., Apuzzo, M. L. J., Giannotta, S. L., Kletzky, O. A., & March, C. M. (1983) · Neurosurgery · doi:10.1227/00006123-198302000-00008 · Cited by 110
Konopka, P., Raymond, J. P., Merceron, R. E., & Sénèze, J. (1983) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(83)90968-7 · Cited by 110
Pituitary Tumor Registry: A Novel Clinical Resource
Drange, M. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.168 · Cited by 108
Long-Term Follow-Up of Prolactinomas: Normoprolactinemia after Bromocriptine Withdrawal
Passos, V. Q., de Souza, J. J. S., Musolino, N. R. D. C., & Bronstein, M. D. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8722 · Cited by 107
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.7.2518 · Cited by 107
Pergolide for the Treatment of Pituitary Tumors Secreting Prolactin or Growth Hormone
Kleinberg, D. L., BOYD, A. E., Wardlaw, S. L., FRANTZ, A. G., GEORGE, A. E., Bryan, R. N., HILAL, S. P., Greising, J., Hamilton, D. J., Seltzer, T. F., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198309223091205 · Cited by 105
Megavoltage pituitary irradiation in the management of prolactinomas: long‐term follow‐up
Tsagarakis, S., Grossman, A. B., Plowman, P. N., et al. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb00312.x · Cited by 105
Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy
Morange, I., Barlier, A., Pellegrini, I., Brue, T. C., Enjalbert, A., & Jaquet, P. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350413 · Cited by 104
The effect of the menopause on prolactin levels in patients with hyperprolactinaemia
Karunakaran, S., Page, R. C., & Wass, J. A. H. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01190.x · Cited by 104
EFFECT OF DOPAMINE AGONIST WITHDRAWAL AFTER LONG-TERM THERAPY IN PROLACTINOMAS
Johnston, D. G., Taylor, P. K., Watson, M., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90480-x · Cited by 103
Forearm and Vertebral Bone Mineral in Treated and Untreated Hyperprolactinemic Amenorrhea*
Schlechte, J., El-Khoury, G. Y., Kathol, M. H., & Walkner, L. M. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-5-1021 · Cited by 103
Barkan, A. L., & Chandler, W. F. (1998) · Neurosurgery · doi:10.1097/00006123-199804000-00126 · Cited by 101
The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas.
Finelli, P., Pierantoni, G. M., Giardino, D. L., Losa, M., Rodeschini, O., Fedele, M., Valtorta, E., Mortini, P., Croce, C. M., Larizza, L., et al. (2002) · PubMed · Cited by 100
Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study
Vergès, B. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.457 · Cited by 100
Cabergoline-Related Severe Restrictive Mitral Regurgitation
Pinero, A., Marcos‐Alberca, P., & Fortes, J. (2005) · New England Journal of Medicine · doi:10.1056/nejm200511033531822 · Cited by 98
Sarno, A. D., Landi, M. L., Marzullo, P., Somma, C. D., Pivonello, R., Cerbone, G., Lombardi, G., & Colao, A. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01016.x · Cited by 98
Necrotic Changes in Prolactinomas after Long Term Administration of Bromocriptine*
Gen, M., Uozumi, T., Ohta, M., et al. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-463 · Cited by 98
Corenblum, B., & Donovan, L. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55819-1 · Cited by 97
Colao, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.6.2247 · Cited by 97
Dopamine, the dopamine D2 receptor and pituitary tumours
Wood, D., Johnston, J., & Johnston, D. G. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb00928.x · Cited by 96
Primary Lymphoma of the Pituitary: An Emerging Clinical Entity
Giustina, A., Gola, M., Doga, M., & Rosei, E. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7909 · Cited by 95
Self-citationClinical history and outcome of 59 patients with idiopathic hyperprolactinemia
Sluijmer, A. V., & Lappöhn, R. E. (1992) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55139-5 · Cited by 92
Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons
DeMaria, J. E., Livingstone, J. D., & Freeman, M. E. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02763-3 · Cited by 86
CICCARELLI, E., Giusti, M., Miola, C., POTENZONI, F., Sghedoni, D., Camanni, F., & Giordano, G. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-4-725 · Cited by 86
Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women
Crosignani, P. G., MATTEI, A. M., Severini, V., Cavioni, V., Maggioni, P., & Testa, G. (1992) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0028-2243(92)90094-f · Cited by 85
Fiorentini, C., Guerra, N., Facchetti, M., Finardi, A., Tiberio, L., Schiaffonati, L., Spano, P., & Missale, C. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.2.0773 · Cited by 82
Resistance to somatostatin analogs in acromegaly: An evolving concept?
Gola, M., Bonadonna, S., Mazziotti, G., Amato, G., & Giustina, A. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03349183 · Cited by 81
Self-citationProlactin-producing microadenomas in pregnancy.
Divers, W. A., & Yen, S. S. C. (1983) · PubMed · Cited by 79
Malignant prolactinoma: case report and review of the literature
Kars, M., Roelfsema, F., Romijn, J. A., & Pereira, A. M. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02268 · Cited by 79
Two-year treatment with oral contraceptives in hyperprolactinemic patients
Testa, G., Vegetti, W., Motta, T., Alagna, F., Bianchedi, D., Carlucci, C., Bianchi, M., Parazzini, F., & Crosignani, P. G. (1998) · Contraception · doi:10.1016/s0010-7824(98)00069-9 · Cited by 75
Burgess, J. R., Shepherd, J. J., Parameswaran, V., Hoffman, L., & Greenaway, T. M. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.5.8626844 · Cited by 73
Novel insights in somatostatin receptor physiology
Tulipano, G., & Schulz, S. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02354 · Cited by 71
Corticosteroid Regulation of Gonadotropin and Prolactin Secretion in the Rat*
Brann, D. W., Putnam, C. D., & Mahesh, V. B. (1990) · Endocrinology · doi:10.1210/endo-126-1-159 · Cited by 68
Vance, M. L., Lipper, M. H., Klibanski, A., Biller, B. M. K., Samaan, N. A., & Molitch, M. E. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-9-668 · Cited by 68
Cabergoline: Long-Acting Oral Treatment of Hyperprolactinemic Disorders
Ferrari, C. I., MATTEI, A. M., Melis, G. B., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-6-1201 · Cited by 67
Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas
Nelson, A. T., Tucker, H. S. G., & Becker, D. P. (1984) · Journal of neurosurgery · doi:10.3171/jns.1984.61.3.0577 · Cited by 66
Enjalbert, A., Epelbaum, J., Arancibia, S., TAPIA-ARANCIBIA, L., Bluet‐Pajot, M., & Kordon, C. (1982) · Endocrinology · doi:10.1210/endo-111-1-42 · Cited by 65
CV 205–502 Treatment of Hyperprolactinemia*
Vance, M. L., Cragun, J. R., REIMNITZ, C., Chang, R. J., RASHEF, E., Blackwell, R. E., MILLER, M. M., & Molitch, M. E. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-336 · Cited by 60
Influence of pregnancies on prolactinomas
Rjosk, H. Κ., Fahlbusch, R., & von Werder, K. (1982) · European Journal of Endocrinology · doi:10.1530/acta.0.1000337 · Cited by 60
Genesis of Prolactinomas: Studies Using Estrogen-Treated Animals
Sarkar, D. K. (2006) · KARGER eBooks · doi:10.1159/000094307 · Cited by 59
Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy
Garcia, M., & Kapcala, L. P. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03349744 · Cited by 58
Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma Shrinkage
Colao, A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3574 · Cited by 55
Lamberts, S. W. J., & Quik, R. F. P. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-3-635 · Cited by 51
A New Mechanism for Prolactin Processing into 16K PRL by Secreted Cathepsin D
Piwnica, D., Fernandez, I., Binart, N., Touraine, P. A., Kelly, P. A., & Goffin, V. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0044 · Cited by 49
Andreotti, A. C., Pianezzola, E., Persiani, S., Pacciarini, M. A., Benedetti, M. S., & Pontiroli, A. E. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.3.841 · Cited by 49
Physiological role of galanin in the regulation of anterior pituitary function in humans
Giustina, A., Licini, M., Schettino, M., Doga, M., Pizzocolo, G., & Negro-Vilar, A. F. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.266.1.e57 · Cited by 49
Self-citationPituitary disorders during pregnancy.
Molitch, M. (2006) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2005.09.011 · Cited by 48
Berezin, M., & Karasik, A. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02666.x · Cited by 44
Management of resistant prolactinomas
Olafsdottir, A., & Schlechte, J. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0290 · Cited by 43
HILL, J. B., Nagy, G. M., & Frawley, L. S. (1991) · Endocrinology · doi:10.1210/endo-129-2-843 · Cited by 43
The Effect of Combined Estrogen/Progestogen Treatment in Women with Hyperprolactinemic Amenorrhea
Fahy, U., Foster, P. A., Torode, H. W., Hartog, M., & Hull, M. G. R. (1992) · Gynecological Endocrinology · doi:10.3109/09513599209015553 · Cited by 41
Johnston, D. G., Hall, K., Kendall-Taylor, P., ROSS, W. M., Crombie, A. L., Cook, D. B., & Watson, M. J. (1986) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1986.tb01664.x · Cited by 41
Antiparkinsonian treatment in pregnancy
Mari, M. D., Zenzola, A., & Lamberti, P. (2002) · Movement Disorders · doi:10.1002/mds.10040 · Cited by 39
Tulipano, G., Bonfanti, C., Milani, G., Billeci, B., Bollati, A., Cozzi, R. C., Maira, G., Murphy, W. A., Poiesi, C., Turazzi, S., et al. (2001) · Neuroendocrinology · doi:10.1159/000054651 · Cited by 39
Self-citationLong-Term Follow-Up of Prolactinomas: Normoprolactinemia after Bromocriptine Withdrawal
Passos, V. Q. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3578 · Cited by 39
Pergolide As Primary Therapy for Macroprolactinomas
Orrego, J. J., Chandler, W. F., & Barkan, A. L. (2000) · Pituitary · doi:10.1023/a:1012836331506 · Cited by 37
Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men
Romeo, J. H., Dombrowski, R. C., Kwak, Y. S., Fuehrer, S. M., & Aron, D. C. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00859.x · Cited by 35
Outcome of pregnancies in women with treated or untreated hyperprolactinemia
Rossi, A.-M., Vilska, S., & Heinonen, P. K. (1995) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0301-2115(95)02257-0 · Cited by 35
Wojcikiewicz, R. J. H., Dobson, P. R. M., & BROWN, B. L. (1984) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(84)90032-6 · Cited by 32
Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration
Melis, G. B., Gambacciani, M., Paoletti, A. M., et al. (1989) · Fertility and Sterility · doi:10.1016/s0015-0282(16)60909-3 · Cited by 31
Popadić, A., Witzmann, A., Buchfelder, M., Eiter, H., & Komminoth, P. (1999) · Surgical Neurology · doi:10.1016/s0090-3019(97)00458-8 · Cited by 30
Sato, K., & Watanabe, Y. (1998) · Archivum histologicum japonicum · doi:10.1679/aohc.61.75 · Cited by 30
Spada, A., Mantovani, G., & Lania, A. G. (2005) · Pituitary · doi:10.1007/s11102-005-5080-7 · Cited by 30
Racagni, G., Apud, J. A., Cocchi, D., Locatelli, V., Iuliano, E., Casanueva, F. F., & Müller, E. E. (1984) · Journal of Endocrinological Investigation · doi:10.1007/bf03348454 · Cited by 29
Self-citationRelative effects of prolactin excess and estrogen deficiency on bone in rats
Adler, R. A., Evani, R., Mansouri, A., & Krieg, R. J. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90054-3 · Cited by 24
FAILURE OF PROPHYLACTIC SURGERY TO AVERT MASSIVE PITUITARY EXPANSION IN PREGNANCY
Belchetz, P. E., CARTY, A., Clearkin, L. G., Davis, J. C., Jeffreys, R. V., & Rae, P. G. (1986) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1986.tb01698.x · Cited by 24
Neuroendocrine Effects of Hypericum Extract WS 5570 in 12 Healthy Male Volunteers
Schüle, C., Baghai, T. C., Ferrera, A., & Laakmann, G. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-15456 · Cited by 23
Role of Central Beta-Adrenoceptors on Stress-Induced Prolactin Release in Rats
Haanwinckel, M. A. S., Antunes-Rodrigues, J., & Silva, E. D. C. E. (1991) · Hormone and Metabolic Research · doi:10.1055/s-2007-1003686 · Cited by 19
Fiorentini, C. (2002) · Molecular Endocrinology · doi:10.1210/me.16.2.353 · Cited by 19
Dexamethasone and Adrenocorticotropin Suppress Prolactin Secretion in Humans
Hubina, E., Nagy, G. M., Tóth, B. E., Iván, G., Görömbey, Z., Szabolcs, I., Kovács, L., & Góth, M. I. (2002) · Endocrine · doi:10.1385/endo:18:3:215 · Cited by 11
Research works printed but not linked: 42
- Bernichtein, 2001, S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist, Endocrinology, 142, 3950, 10.1210/endo.142.9.8369 · doi:10.1210/endo.142.9.8369
- Wu, 2003, Different biological effects of unmodified PRL and a molecular mimic of phosphorylated PRL involve different signaling pathways, Biochemistry, 42, 7561, 10.1021/bi034217s · doi:10.1021/bi034217s
- De Marinis, 2000, Effects of galanin on growth hormone and PRL secretion in anorexia nervosa, Metabolism, 49, 155, 10.1016/S0026-0495(00)91091-6 · doi:10.1016/s0026-0495(00)91091-6
- Lafuente, 2005, Toxic effects of cadmium on the regulatory mechanism of dopamine and serotonin on PRL secretion in adult male rats, Toxicol Lett, 155, 87, 10.1016/j.toxlet.2004.08.011 · DOI
- Niu, 2004, Neurobehavioral functions, serum PRL and plasma renin activity of manganese-exposed workers, Int J Immunopathol Pharmacol, 17, 17, 10.1177/03946320040170S204 · doi:10.1177/03946320040170s204
- Lucchini, 2000, Assessment of neurobehavioral performance as a function of current and cumulative occupational lead exposure, Neurotoxicology, 21, 805
- Alessio, 2006, Prolactin changes as a consequence of chemical exposure, Environ Health Perspect, 114, A573, 10.1289/ehp.114-a573 · doi:10.1289/ehp.114-a573
- Waschek, 1987, Barium distinguishes separate calcium targets for synthesis and secretion of peptides in neuroendocrine cells, Biochem Biophys Res Commun, 146, 495, 10.1016/0006-291X(87)90556-0 · doi:10.1016/0006-291x(87)90556-0
- Vrkljan, 2006, Incidence of pituitary tumors in the human population of Croatia, Coll Antropol, 30, 157
- Zargar, 2004, Clinical and endocrine aspects of pituitary tumors, Saudi Med J, 25, 1428
- Fideleff, 2000, Peripubertal prolactinoma: clinical presentation and long-term outcome with different therapeutic approaches, J Pediatr Endocrinol Metab, 13, 261, 10.1515/JPEM.2000.13.3.261 · doi:10.1515/jpem.2000.13.3.261
- Mindermann, 1995, Pituitary adenomas in childhood and adolescence, J Pediatr Endocrinol Metab, 8, 79, 10.1515/JPEM.1995.8.2.79 · doi:10.1515/jpem.1995.8.2.79
- Daly, 2006, Clinical characterization of familial isolated pituitary adenomas, J Clin Endocrinol Metab, 91, 3316, 10.1210/jc.2005-2671 · doi:10.1210/jc.2005-2671
- Karga, 1992, Ras mutations in human pituitary tumors, J Clin Endocrinol Metab, 74, 914, 10.1210/jcem.74.4.1312542 · doi:10.1210/jcem.74.4.1312542
- Cristina, 2007, PTTG expression in different experimental and human prolactinoma in relation to dopaminergic control of lactotropes, Mol Cancer, 6, 1, 10.1186/1476-4598-6-4 · doi:10.1186/1476-4598-6-4
- Horwitz, 2003, Human pituitary tumor-transforming gene (PTTG1) motif suppresses PRL expression, Mol Endocrinol, 17, 600, 10.1210/me.2001-0006 · doi:10.1210/me.2001-0006
- Sigala, 2004, Increased serum concentration of nerve growth factor in patients with microprolactinoma, Neuropeptides, 38, 21, 10.1016/j.npep.2003.11.002 · doi:10.1016/j.npep.2003.11.002
- Smith, 2007, Technology insight: measuring PRL in clinical samples, Nat Clin Pract Endocrinol Metab, 3, 279, 10.1038/ncpendmet0447 · DOI
- Quinn, 2006, Determination of ultrafilterable PRL: elimination of macroprolactin interference with a monomeric PRL-selective sample pretreatment, Arch Pathol Lab Med, 130, 1807, 10.5858/2006-130-1807-DOUPEO · doi:10.5858/2006-130-1807-doupeo
- Hauache, 2002, Screening for macroprolactinaemia and pituitary imaging studies, Clin Endocrinol (Oxf), 57, 327, 10.1046/j.1365-2265.2002.01586.x · doi:10.1046/j.1365-2265.2002.01586.x
- Ambrosi, 1980, PRL and sexual function, JAMA, 244, 2608, 10.1001/jama.1980.03310230014010 · doi:10.1001/jama.1980.03310230014010
- Orrego, 2000, Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine, Pituitary, 3, 189, 10.1023/A:1011412028660 · doi:10.1023/a:1011412028660
- Wass, 2006, When to discontinue treatment of prolactinoma?, Nat Clin Pract Endocrinol Metab, 2, 298, 10.1038/ncpendmet0162 · doi:10.1038/ncpendmet0162
- Bronstein, 2006, Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy, Nat Clin Pract Endocrinol Metab, 2, 130, 10.1038/ncpendmet0135 · doi:10.1038/ncpendmet0135
- Crosignani, 1978, Antiserotonin treatment of hyperprolactinemic amenorrhea: long-term follow-up with metergoline, methysergide, and cyproheptadine, Am J Obstet Gynecol, 132, 307, 10.1016/0002-9378(78)90898-0 · doi:10.1016/0002-9378(78)90898-0
- Bohnet, 1986, Treatment of hyperprolactinemic amenorrhea with Metergoline, Obstet Gynecol, 67, 249, 10.1097/00006250-198602000-00016 · doi:10.1097/00006250-198602000-00016
- Weiss, 1983, Bromocriptine treatment of PRL-secreting tumors: surgical implications, Neurosurgery, 12, 640, 10.1227/00006123-198306000-00008 · doi:10.1227/00006123-198306000-00008
- Kissner, 1980, Side effects of bromocriptine, N Engl J Med, 302, 749, 10.1056/NEJM198003273021313 · doi:10.1056/nejm198003273021313
- Pearson, 1981, Mental disorders from low-dose bromocriptine, N Engl J Med, 305, 173, 10.1056/NEJM198107163050321 · doi:10.1056/nejm198107163050321
- Baskin, 1982, CSF rhinorrhea after bromocriptine for prolactinoma, N Engl J Med, 306, 178, 10.1056/NEJM198201213060322 · doi:10.1056/nejm198201213060322
- Franks, 1981, Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment, Lancet, 2, 659, 10.1016/S0140-6736(81)90997-1 · doi:10.1016/s0140-6736(81)90997-1
- Giusti, 1994, A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients, J Endocrinol Invest, 17, 51, 10.1007/BF03344963 · doi:10.1007/bf03344963
- Jaquet, 1999, Quantitative and functional expression of somatostatin receptor subtypes in human prolactinoma, J Clin Endocrinol Metab, 84, 3268
- Jaquet, 2005, Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and PRL secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy, Eur J Endocrinol, 153, 135, 10.1530/eje.1.01950 · doi:10.1530/eje.1.01950
- Cappabianca, 2004, Endoscopic endonasal transsphenoidal surgery, Neurosurgery, 55, 933, 10.1227/01.NEU.0000137330.02549.0D · doi:10.1227/01.neu.0000137330.02549.0d
- Thomson, 1994, Ten year follow up of microprolactinoma treated by transsphenoidal surgery, BMJ, 309, 1409, 10.1136/bmj.309.6966.1409 · doi:10.1136/bmj.309.6966.1409
- Amar, 2002, Predictive value of serum PRL levels measured immediately after transsphenoidal surgery, J Neurosurg, 97, 307, 10.3171/jns.2002.97.2.0307 · doi:10.3171/jns.2002.97.2.0307
- Landolt, 1982, Bromocriptine: does it jeopardise the result of later surgery for prolactinoma?, Lancet, 2, 657, 10.1016/S0140-6736(82)92756-8 · doi:10.1016/s0140-6736(82)92756-8
- Fahlbusch, 1984, Influence of preoperative bromocriptine therapy on success of surgery for microprolactinoma, Lancet, 2, 520, 10.1016/S0140-6736(84)92596-0 · doi:10.1016/s0140-6736(84)92596-0
- Kuo, 2004, Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes, Neurosurgery, 54, 1385, 10.1227/01.NEU.0000124750.13721.94 · doi:10.1227/01.neu.0000124750.13721.94
- Landolt, 2000, Gamma knife radiosurgery for prolactinoma, J Neurosurg, 93, 14, 10.3171/jns.2000.93.supplement_3.0014 · doi:10.3171/jns.2000.93.supplement_3.0014
- Ahmed, 1992, Macroprolactinoma with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies, Fertil Steril, 58, 492, 10.1016/S0015-0282(16)55250-9 · doi:10.1016/s0015-0282(16)55250-9
Cited by
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Self-citationClinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Evaluation and Management of Testosterone Deficiency: AUA Guideline
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.03.115 · Cited by 766
Petersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00886-5 · Cited by 411
Self-citation
Metadata
- Authors
- Mancini, T., Casanueva, F. F., & Giustina, A.
- Venue
- Endocrinology and Metabolism Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 37
- Issue
- 1
- Pages
- 67-99
- ISSN
- 0889-8529 (ISSN-L)
- OpenAlex
- W2073194318
- Cited by
- 256
- References
- 157
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.